Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1.

Stolla M, Pelisek J, von Brühl ML, Schäfer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S, Schulz C.

PLoS One. 2012;7(8):e43572. doi: 10.1371/journal.pone.0043572. Epub 2012 Aug 20.

2.

Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules.

Butoi ED, Gan AM, Manduteanu I, Stan D, Calin M, Pirvulescu M, Koenen RR, Weber C, Simionescu M.

Biochim Biophys Acta. 2011 Dec;1813(12):2026-35. doi: 10.1016/j.bbamcr.2011.08.009. Epub 2011 Aug 22.

3.

Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway.

Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K, Irani K, Becker LC.

Circ Res. 2007 Nov 9;101(10):1001-8. Epub 2007 Sep 20.

4.

[Expressions of fractalkine and CD11c on common carotid artery atherosclerotic plaques from apoE(-/-) mice].

Xu ZX, Lu LM, Zhang YG, Zhang GB.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Oct;35(5):519-23. doi: 10.3881/j.issn.1000-503X.2013.05.007. Chinese.

5.

Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis.

Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JC, Koch AE.

Arthritis Rheum. 2001 Jul;44(7):1568-81.

6.

Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice.

Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, Charles FS, Lesnik P, Deterre P, Combadiere C.

Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2297-305. doi: 10.1161/ATVBAHA.112.300930. Epub 2013 Jul 25.

7.

Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.

Ryu J, Lee CW, Hong KH, Shin JA, Lim SH, Park CS, Shim J, Nam KB, Choi KJ, Kim YH, Han KH.

Cardiovasc Res. 2008 May 1;78(2):333-40. Epub 2007 Nov 11.

8.
9.

Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models.

Nakatani K, Yoshimoto S, Iwano M, Asai O, Samejima K, Sakan H, Terada M, Hasegawa H, Nose M, Saito Y.

Am J Physiol Renal Physiol. 2010 Jul;299(1):F207-16. doi: 10.1152/ajprenal.00482.2009. Epub 2010 Apr 21.

10.

Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients.

Yano R, Yamamura M, Sunahori K, Takasugi K, Yamana J, Kawashima M, Makino H.

Acta Med Okayama. 2007 Apr;61(2):89-98.

11.

Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.

Patel A, Jagadesham VP, Porter KE, Scott DJ, Carding SR.

Eur J Vasc Endovasc Surg. 2008 Jul;36(1):20-7. doi: 10.1016/j.ejvs.2008.01.014. Epub 2008 Mar 4.

12.

Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes.

Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, Kamada N, Imai T, Goto H, Hibi T.

Inflamm Bowel Dis. 2007 Jul;13(7):837-46.

PMID:
17285595
13.

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.

Martínez-Hervás S, Vinué A, Núñez L, Andrés-Blasco I, Piqueras L, Real JT, Ascaso JF, Burks DJ, Sanz MJ, González-Navarro H.

Cardiovasc Res. 2014 Jul 15;103(2):324-36. doi: 10.1093/cvr/cvu115. Epub 2014 Apr 29.

14.

Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis.

You JJ, Yang CH, Huang JS, Chen MS, Yang CM.

Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5290-8.

PMID:
17962485
15.

Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice.

Song KH, Park J, Park JH, Natarajan R, Ha H.

Diabetologia. 2013 Jul;56(7):1661-9. doi: 10.1007/s00125-013-2907-z. Epub 2013 Apr 19.

16.

Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability.

Zhang X, Feng X, Cai W, Liu T, Liang Z, Sun Y, Yan C, Han Y.

Thromb Res. 2015 Jun;135(6):1147-53. doi: 10.1016/j.thromres.2015.03.020. Epub 2015 Mar 20.

PMID:
25845619
17.

Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets.

Schulz C, Schäfer A, Stolla M, Kerstan S, Lorenz M, von Brühl ML, Schiemann M, Bauersachs J, Gloe T, Busch DH, Gawaz M, Massberg S.

Circulation. 2007 Aug 14;116(7):764-73. Epub 2007 Aug 6.

18.

Fractalkine/CX3CR1 and atherosclerosis.

Liu H, Jiang D.

Clin Chim Acta. 2011 Jun 11;412(13-14):1180-6. doi: 10.1016/j.cca.2011.03.036. Epub 2011 Apr 6. Review.

PMID:
21492740
19.

Lipopolysaccharide increases monocyte binding to mesangial cells through fractalkine and its receptor.

Park J, Song KH, Ha H.

Transplant Proc. 2012 May;44(4):1029-31. doi: 10.1016/j.transproceed.2012.03.046.

PMID:
22564617
20.

Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis.

Saederup N, Chan L, Lira SA, Charo IF.

Circulation. 2008 Apr 1;117(13):1642-8. doi: 10.1161/CIRCULATIONAHA.107.743872. Epub 2007 Dec 28.

Items per page

Supplemental Content

Write to the Help Desk